Levin Capital Strategies, L.P. Summit Therapeutics Inc. Transaction History
Levin Capital Strategies, L.P.
- $1.03 Billion
- Q3 2024
A detailed history of Levin Capital Strategies, L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 36,176 shares of SMMT stock, worth $777,422. This represents 0.08% of its overall portfolio holdings.
Number of Shares
36,176
Previous 39,176
7.66%
Holding current value
$777,422
Previous $305,000
159.67%
% of portfolio
0.08%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
173Shares Held
70.4MCall Options Held
1.3MPut Options Held
2.06M-
Baker Bros. Advisors LP New York, NY23.2MShares$499 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$235 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$170 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$88.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$66.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.32B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...